肺动脉高血压药物市场按药物类别、给药途径、类型、性别、通路和地区划分

2025 年全球肺动脉高血压药物市场规模估计为 85.8 亿美元，预计到 2032 年将达到 128.1 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 5.9%。

数字。 2025 年肺动脉高血压治疗市场占有率（按地区划分）

过去几年，全球肺动脉高血压药物市场一直稳定成长。肺动脉高血压是一种以连接心臟和肺部的动脉血压异常高的疾病。过大的压力会使心臟更难将血液泵入肺部以获取氧气。如果延迟治疗，病情可能会恶化并导致心臟衰竭。由于风险因素的增加、新的有效治疗药物的核准以及诊断技术的改进，肺动脉高血压盛行率不断上升，推动了全球对特定药物的需求。然而，治疗费用高昂以及长期用药的副作用仍然是主要挑战。

市场动态：

全球肺动脉高血压药物市场受到多种因素的推动，例如由于人口老化、遗传易感性和其他医疗状况等风险因素的增加而导致肺动脉高血压盛行率不断上升。美国国家医学图书馆估计，到2024年11月，北美和欧洲将有超过10万人患有肺动脉高血压。此外，前列腺环素类似物、内皮素受体拮抗剂和磷酸二酯酶 5 抑制剂等疗效和便利性更高的新药的核准也推动了市场的成长。然而，品牌药物的高价格仍然是一个主要阻碍因素。治疗肺动脉高血压需要终生服药，每年花费数千美元。这限制了人们获得药物的机会。不过，低成本学名药的出现有望为市场参与者创造新的机会。

本研究的主要特点

本报告对全球肺动脉高血压治疗市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模和年复合成长率（CAGR%）。

它还强调了各个领域的潜在商机并说明了该市场的有吸引力的投资提案矩阵。

它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。

全球肺动脉高血压治疗市场的主要企业是根据公司亮点、产品系列、关键亮点、业绩和策略等参数进行介绍的。

这项研究涉及的主要企业包括 United Therapeutics Corporation、Actelion Pharmaceuticals（杨森製药公司旗下一家）、拜耳公司、吉利德科学公司、默克公司、葛兰素史克公司、辉瑞公司、诺华国际公司、Teva Pharmaceutical Industries Ltd.、安进公司、百时山公司、Arena Pharmaceticals、Arena Pharmaceticals.

本报告的见解将使负责人和企业经营团队能够就未来产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。

全球肺动脉高血压治疗药物市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。

相关人员可以透过用于分析全球肺动脉高血压药物市场的各种策略矩阵来促进决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章市场动态、法规与趋势分析

• 市场动态
• 司机
• 限制因素
• 机会
• 影响分析
• 主要进展
• 监管情景
• 产品发布/核准
• PEST分析
• PORTER 分析
• 併购情景
• 产业趋势

4. 2020 年至 2032 年按药物类别分類的全球肺动脉高血压药物市场

• 前列腺环素和前列腺环素类似物
• 内皮素受体拮抗剂 (ERA)
• 磷酸二酯酶 5 抑制剂（PDE-5 抑制剂）
• 可溶性鸟苷酸环化酶 (sGC) 刺激剂
• 其他药物类别

5. 2020 年至 2032 年按给药途径分類的全球肺动脉高血压药物市场

• 口服
• 静脉
• 皮下
• 吸入

6. 2020 年至 2032 年全球肺动脉高血压药物市场（按类型）

• 品牌药品
• 学名药

7. 2020 年至 2032 年全球肺动脉高血压药物市场（依性别划分）

• 男性
• 女士

8. 2020 年至 2032 年按通路分類的全球肺动脉高血压药物市场

• 医院药房
• 零售药局
• 网路药局

9. 2020 年至 2032 年全球肺动脉高血压药物市场（按地区划分）

• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第十章 竞争格局

• United Therapeutics Corporation
• Actelion Pharmaceuticals
• Bayer AG
• Gilead Sciences, Inc.
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis International AG
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Arena Pharmaceuticals
• Sun Pharmaceutical Industries Ltd.
• Sandoz Inc.
• Lupin Pharmaceuticals, Inc.

第 11 章 分析师建议

• 命运之轮
• 分析师观点
• 一致的机会图

第 12 章参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Global Pulmonary Arterial Hypertension Drug Market is estimated to be valued at US$ 8.58 Bn in 2025 and is expected to reach US$ 12.81 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032.

Figure. Pulmonary Arterial Hypertension Drug Market Share (%), By Region 2025

The global pulmonary arterial hypertension drug market has been witnessing steady growth over the past few years. Pulmonary arterial hypertension is a condition characterized by abnormally high blood pressure in the arteries connecting the heart and lungs. The excessive pressure makes the heart work harder to pump blood through the lungs to obtain oxygen. If not treated on time, the condition can lead to worsening symptoms and even heart failure. Factors such as the growing prevalence of pulmonary arterial hypertension due to increasing risk factors, approval of new and effective treatment drugs, and improved diagnosis are driving the demand for specific drugs globally. However, high treatment costs and side effects associated with long term use of drugs continue to remain major challenges.

Market Dynamics:

The global pulmonary arterial hypertension drug market is driven by factors such as the increasing prevalence of pulmonary arterial hypertension due to growing risk factors like older age, genetic predisposition, and other medical conditions. In November 2024, according to National Library of Medicine estimates, more than 100,000 people in North America and Europe suffer from pulmonary arterial hypertension. Furthermore, approval of new drugs such as prostacyclin analogs, Endothelin receptor antagonists, Phosphodiesterase-5 inhibitors, and others which offer improved efficacy and convenience is also fueling market growth. However, the high cost of branded drugs remains a key restraint. Treatment of pulmonary arterial hypertension requires life-long medication which costs thousands of dollars every year. This limits accessibility to medication. Nevertheless, emergence of low-cost generic drugs is expected to create new opportunities for market players.

Key Features of the Study:

This report provides in-depth analysis of the global pulmonary arterial hypertension drug market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global pulmonary arterial hypertension drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include United Therapeutics Corporation, Actelion Pharmaceuticals (a Janssen Pharmaceutical Company), Bayer AG, Gilead Sciences, Inc., Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Novartis International AG, Teva Pharmaceutical Industries Ltd., Amgen Inc., Bristol-Myers Squibb Company, Arena Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Sandoz Inc., and Lupin Pharmaceuticals, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global pulmonary arterial hypertension drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pulmonary arterial hypertension drug market

Market Segmentation

• Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
  • Prostacyclin and Prostacyclin Analogs
  • Endothelin Receptor Antagonists (ERAs)
  • Phosphodiesterase-5 Inhibitors (PDE-5 Inhibitors)
  • Soluble Guanylate Cyclase (sGC) Stimulators
  • Other Drug Classes
• Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Intravenous
  • Subcutaneous
  • Inhalation
• Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Branded Drugs
  • Generic Drugs
• Gender Insights (Revenue, USD Bn, 2020 - 2032)
  • Male
  • Female
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • United Therapeutics Corporation
  • Actelion Pharmaceuticals
  • Bayer AG
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Novartis International AG
  • Teva Pharmaceutical Industries Ltd.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Arena Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz Inc.
  • Lupin Pharmaceuticals, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Pulmonary Arterial Hypertension Drug Market, By Drug Class
  • Global Pulmonary Arterial Hypertension Drug Market, By Route of Administration
  • Global Pulmonary Arterial Hypertension Drug Market, By Type
  • Global Pulmonary Arterial Hypertension Drug Market, By Gender
  • Global Pulmonary Arterial Hypertension Drug Market, By Distribution Channel
  • Global Pulmonary Arterial Hypertension Drug Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Pulmonary Arterial Hypertension Drug Market, By Drug Class, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Prostacyclin and Prostacyclin Analogs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Endothelin Receptor Antagonists (ERAs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Phosphodiesterase-5 Inhibitors (PDE-5 Inhibitors)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Soluble Guanylate Cyclase (sGC) Stimulators
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other Drug Classes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Pulmonary Arterial Hypertension Drug Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Subcutaneous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Inhalation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Pulmonary Arterial Hypertension Drug Market, By Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Branded Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Generic Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Pulmonary Arterial Hypertension Drug Market, By Gender, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Male
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Female
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Pulmonary Arterial Hypertension Drug Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Pulmonary Arterial Hypertension Drug Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• United Therapeutics Corporation
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Actelion Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Gilead Sciences, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis International AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc.
• Bristol-Myers Squibb Company
• Arena Pharmaceuticals
• Sun Pharmaceutical Industries Ltd.
• Sandoz Inc.
• Lupin Pharmaceuticals, Inc.

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us